The development of advanced artificial intelligence (AI), particularly large language models and generative AI, has started to impact basic science, clinical research, clinical practice, and everyday life. In the last three years, several applications of generative AI to drug discovery and clinical trial design have emerged and together have the potential to accelerate drug development timelines and impart major impacts on human health.
Researchers in both fundamental and clinical research areas must be aware of these advances to incorporate them in their own academic work and to critically evaluate molecules and clinical trials driven by generative AI.
Learning Objectives
Upon completion of the program, the participant will be able to:
- Discuss potential applications of generative AI in the analysis of large-scale molecular omics data and clinical trial design, including enrichment and event adjudication
- Describe the use of generative AI in prescreening, screening, and enrollment eligibility for clinical trials
- Identify strategies that use generative AI to better understand disease pathophysiology and translate clinical research findings to practice.
Target Audience
- Physicians
- Researchers
- Medical and Other Trainees
- Nurses and Nurse Practitioners
- Pharmacists
- Physician Assistants
- Other Healthcare Professionals
Acknowledgement
ASN thanks the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Dr. Eric Brunskill, and Dr. Debbie Gipson for their assistance with this program. Congratulations to NIDDK on its 75th anniversary.
Privacy Policy/Confidentiality
http://www.asn-online.org/terms/privacy.aspx
ASN Medical Disclaimer
http://www.asn-online.org/terms/medical-disclaimer.aspx